CD19 and diffuse large B-cell lymphoma: Key trials testing CD19 CAR T‐cell therapy as initial treatment for DLBCL such as ZUMA‐12 [32] and ZUMA‐23 [33] exclude tiNHL patients who have received prior treatment for their indolent lymphoma.